Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24159907 | 0.80 | ADORA2A (0.37) | ADORA1ADORA2A | |
| SCHEMBL7926347 | 0.75 | ADORA1 (0.48) | ADORA1ADORA2AKMT2AGAAKDM4E | |
| SCHEMBL29727928 | 0.73 | KMT2A (0.53) | ADORA1ADORA2AKMT2AGAAKDM4E | |
| SCHEMBL2160239 | 0.73 | KMT2A (0.53) | ADORA1ADORA2AKMT2AGAAKDM4E | |
| SCHEMBL1553593 | 0.72 | ADORA1 (0.46) | ADORA1ADORA2AKMT2AGAAKDM4E | |
| SCHEMBL12525866 | 0.72 | ADORA1 (0.46) | ADORA1ADORA2AKMT2AGAAKDM4E | |
| SCHEMBL30445560 | 0.72 | ADORA1 (0.46) | ADORA1ADORA2AKMT2AGAAKDM4E | |
| SCHEMBL10884409 | 0.72 | KMT2A (0.46) | ADORA1ADORA2AKMT2AGAAKDM4E | |
| SCHEMBL22239632 | 0.70 | ADORA1 (0.44) | ADORA1ADORA2AKMT2AGAAKDM4E | |
| SCHEMBL13119660 | 0.69 | ADORA1 (0.43) | ADORA1ADORA2AKMT2AGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | THE UNIVERSITY OF TOKYO (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170145005-A1 | KINASE INHIBITOR | THE UNIVERSITY OF TOKYO (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170145005-A1 | KINASE INHIBITOR | THE UNIVERSITY OF TOKYO (JP) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | PIM3, PIM1, PIM2 | ADORA1 4825/4885ADORA2A 4855/4885KMT2A 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.